A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland

被引：0
|
作者：
Felicity Lamrock
Laura McCullagh
Lesley Tilson
Michael Barry
机构：
[1] Queen’s University Belfast,Department of Pharmacology and Therapeutics
[2] National Centre for Pharmacoeconomics,undefined
[3] St James’s Hospital,undefined
[4] Trinity College Dublin,undefined
来源：
The European Journal of Health Economics | 2020年 / 21卷
关键词：
Budget impact analysis; Buget impact model; Health Technology Assessment; Reimbursement; New drugs; Ireland; H61 Budgets; E42 Payment Systems; L65 Drugs; O52 Europe; G18 Government Policy and Regulation; C60 General;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：895 / 901
页数：6
相关论文
共 50 条
  • [1] A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland
    Lamrock, Felicity
    McCullagh, Laura
    Tilson, Lesley
    Barry, Michael
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (06): : 895 - 901
  • [2] EXAMINING THE CONSISTENCY AND ACCURACY OF THE BUDGET IMPACT MODELS SUBMITTED TO THE NATIONAL CENTRE FOR PHARMACOECONOMICS IN IRELAND TO AID THE CREATION OF AN APPLICANT TEMPLATE
    Lamrock, F.
    Tilson, L.
    McCullagh, L.
    Barry, M.
    VALUE IN HEALTH, 2018, 21 : S312 - S312
  • [3] SURVIVAL ANALYSIS USED IN COMPANY SUBMISSIONS TO THE NATIONAL CENTRE FOR PHARMACOECONOMICS, IRELAND
    McCullagh, L.
    Barry, M.
    VALUE IN HEALTH, 2013, 16 (07) : A398 - A398
  • [4] DEVELOPMENT OF THE PATIENT ORGANISATION SUBMISSION PROCESS IN THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE), IRELAND
    Hanevy, A.
    Gorry, C.
    Tilson, L.
    O'Leary, A.
    Barry, M.
    VALUE IN HEALTH, 2018, 21 : S151 - S151
  • [5] A REVIEW OF PHARMACOECONOMIC EVALUATIONS OF NEW AND EXISTING TECHNOLOGIES BY THE NATIONAL CENTRE FOR PHARMACOECONOMICS IN IRELAND
    Tilson, L.
    O'Leary, A.
    Usher, C.
    Barry, M.
    VALUE IN HEALTH, 2009, 12 (07) : A250 - A250
  • [6] RETROSPECTIVE BUDGET IMPACT ANALYSIS ON THE USE OF THE ONCOTYPE DX® TEST IN IRELAND
    Falahee, M.
    Plun-Favreau, J.
    Ercoli, K.
    BREAST, 2013, 22 : S112 - S112
  • [7] SURVEY OF THE PATIENT ORGANISATION SUBMISSION PROCESS (POSP) TO THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE) IN IRELAND
    Gorry, C.
    Hanevy, A.
    O'Leary, A.
    Tilson, L.
    Barry, M.
    VALUE IN HEALTH, 2018, 21 : S151 - S151
  • [8] Precision Versus Non-Precision Oncology Drug Submissions to the National Centre for Pharmacoeconomics in Ireland
    Agh, T.
    Hiligsmann, M.
    Jakab, I
    Beaudart, C.
    Manias, E.
    Borah, B.
    Pednekar, P.
    Zeber, J.
    Turcu-Stiolica, A.
    Daly, C.
    Shah, C.
    Atal, S.
    Sharma, M.
    Zhao, Y.
    Dimitrova, M.
    Kamat, S.
    Milky, G.
    Hutchinson, D.
    Gangan, N.
    Unni, E.
    Brzozowska, M.
    Hajimiri, S. H.
    Janodia, M.
    Peterson, A.
    VALUE IN HEALTH, 2022, 25 (12) : S334 - S334
  • [9] A budget impact analysis of natalizumab use in Ireland
    A. Dee
    M. Hutchinson
    D. De La Harpe
    Irish Journal of Medical Science, 2012, 181 : 199 - 204
  • [10] A budget impact analysis of natalizumab use in Ireland
    Dee, A.
    Hutchinson, M.
    De La Harpe, D.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2012, 181 (02) : 199 - 204
12345